Although small cell neuroendocrine carcinoma of the ureter (ureteral SCNEC) is rare, it always leads to a poor prognosis. Also, no treatment recommendation has been given for ureteral SCNEC, with only PD-1/PD-L1 inhibitors being used for its treatment. Here, we report a case of atypical symptoms of cardiac infarction caused by a PD-1 inhibitor used in the treatment of ureteral SCNEC and hope to address concerns regarding the possible cardiac toxicity caused by PD-1/PD-L1 inhibitors in ureteral SCNEC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073532 | PMC |
| http://dx.doi.org/10.3389/fonc.2023.1114397 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ureter mixed neuroendocrine-non-neuroendocrine neoplasm: a case report and literature review.
Front Oncol
May 2024
Department of Pathology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
Article Synopsis
- A 71-year-old man presented with painless hematuria and weight loss, leading to the discovery of a rare mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) attached to his ureter.
- The tumor was composed of small cell neuroendocrine carcinoma (SCNEC) and adenocarcinoma, each showing distinct immunohistochemical markers which helped in identifying the types of cancerous cells present.
- After undergoing surgery, the patient received chemotherapy and a follow-up CT scan seven months later showed no signs of disease recurrence, highlighting the importance of early diagnosis and treatment for this aggressive type of cancer.
Ureteral small cell neuroendocrine carcinoma: A case report and short review.
Int J Surg Case Rep
October 2023
Department of Pathology Anatomy, Faculty of Medicine, Airlangga University, Surabaya, Indonesia; Dr. Soetomo General-Academic Hospital, Surabaya, East Java, Indonesia.
Introduction And Importance: Primary small cell neuroendocrine carcinoma (SCNEC) in the urinary tract represents less than 0.5 % of urinary tract cancers, and bladder or prostate are the most common sites. Early diagnosis and treatment of ureteral SCNECs are challenging due to nonspecific clinical symptoms and radiographic findings.
View Article and Find Full Text PDFCardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: A case report.
Front Oncol
March 2023
Department of Oncology, the People's Hospital of Yubei District of Chongqing City, Chongqing, China.
Although small cell neuroendocrine carcinoma of the ureter (ureteral SCNEC) is rare, it always leads to a poor prognosis. Also, no treatment recommendation has been given for ureteral SCNEC, with only PD-1/PD-L1 inhibitors being used for its treatment. Here, we report a case of atypical symptoms of cardiac infarction caused by a PD-1 inhibitor used in the treatment of ureteral SCNEC and hope to address concerns regarding the possible cardiac toxicity caused by PD-1/PD-L1 inhibitors in ureteral SCNEC patients.
View Article and Find Full Text PDFImaging manifestations of small cell neuroendocrine carcinoma of the ureter.
Clin Case Rep
January 2023
Department of Ultrasound, Affiliated Dongguan Hospital Southern Medical University, Dongguan People's Hospital Dongguan China.
Small cell neuroendocrine carcinoma (SCNEC) of the ureter is a rare malignant tumor originating from the metaplasia of urothelial cells. This report presents a case of ureteral SCNEC that was preliminarily disclosed by computed tomography; thereafter, transabdominal ultrasonography, transrectal ultrasonography, and magnetic resonance urography were performed to characterize the mass.
View Article and Find Full Text PDFHyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report.
Front Oncol
August 2021
Department of Radiation Oncology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Background: Primary small cell neuroendocrine carcinoma (SCNEC) in the ureter is extremely rare and has been sporadically reported in case reports. Its incidence, diagnosis, treatment, and outcomes have not yet been thoroughly understood. Here we present a patient with advanced SCNEC in the ureter who was treated by multimodal strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!